<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        90-116-14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OMNITROPE 3.3 MG/ML Solution for injection in cartridge 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SOMATROPIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        3.3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in cartridge
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Cartridge
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1568
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Novartis Pharmaceutical Manufacturing GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Novartis Pharmaceutical Manufacturing GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H01AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Omnitrope is a recombinant human growth hormone (also called somatropin). It has the same structure as natural human growth hormone which is needed for bones and muscles to grow. It also helps your fat and muscle tissues to develop in the right amounts. It is recombinant meaning it is not made from human or animal tissue.</p><p><strong>In children Omnitrope is used to treat the following growth disturbances:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are not growing properly and you do not have enough of your own growth hormone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have Turner syndrome. Turner syndrome is a genetic disorder in girls that can affect growth &ndash; your doctor will have told you if you have this.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have chronic renal (kidney) insufficiency. As kidneys lose their ability to function normally, this can affect growth.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you were small or too light at birth. Growth hormone can help you grow taller if you have not been able to catch up or maintain normal growth by 4&nbsp;years of age or later.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have Prader-Willi syndrome (a chromosomal disorder). Growth hormone will help you grow taller if you are still growing, and will also improve your body composition. Your excessive fat will decrease and your reduced muscle mass will improve.</p><p><strong>In adults Omnitrope is used to:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat persons with pronounced growth hormone deficiency. This can start during either adult life or it can continue from childhood.</p><p>If you have been treated with Omnitrope for growth hormone deficiency during childhood, your growth hormone status will be retested after completion of growth. If severe growth hormone deficiency is confirmed, your doctor will propose continuation of Omnitrope treatment.</p><p>You should only be given this medicine by a doctor who has experience with growth hormone treatment and who has confirmed your diagnosis.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Omnitrope</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic (hypersensitive) to somatropin or to any of the other ingredients of Omnitrope.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and tell your doctor if you have an active tumour (cancer). Tumours must be inactive and you must have finished your anti-tumour treatment before you start your treatment with Omnitrope.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and tell your doctor if Omnitrope has been prescribed to stimulate growth but you have already stopped growing (closed epiphyses).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are seriously ill (for example, complications following open heart surgery, abdominal surgery, accidental trauma, acute respiratory failure, or similar conditions). If you are about to have, or have had, a major operation, or go into hospital for any reason, tell your doctor and remind the other doctors you are seeing that you use growth hormone.</p><p><strong>Warnings and precautions</strong></p><p><strong>Talk to your doctor before using Omnitrope.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a replacement therapy with glucocorticoids, you should consult your doctor regularly, as you may need adjustment of your glucocorticoid dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are at risk of developing diabetes, your doctor will need to monitor your blood sugar level during therapy with somatropin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have diabetes, you should closely monitor your blood sugar level during treatment with somatropin and discuss the results with your doctor to determine whether you need to change the dose of your medicines to treat diabetes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After starting somatropin treatment some patients may need to start thyroid hormone replacement.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are receiving treatment with thyroid hormones it may become necessary to adjust your thyroid hormone dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have raised intracranial pressure (which causes symptoms, such as strong headache, visual disturbances or vomiting) you should inform your doctor about it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you walk with a limp or if you start to limp during your growth hormone treatment, you should inform your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are receiving somatropin for growth hormone deficiency following a previous tumour (cancer), you should be examined regularly for recurrence of the tumour or any other cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience worsening abdominal pain you should inform your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Experience in patients above 80 years is limited. Elderly persons may be more sensitive to the action of somatropin, and therefore may be more prone to develop side effects.</p><p>&middot;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Omnitrope may cause an inflammation of the pancreas, which causes severe pain in the abdomen and back. Contact your doctor if you or your child develops stomach ache after taking Omnitrope.</p><p>&nbsp;</p><p><strong>Children with chronic renal (kidney) insufficiency</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor should examine your kidney function and your growth rate before starting somatropin. Medical treatment for your kidney should be continued. Somatropin treatment should be stopped at kidney transplantation.</p><p><strong>Children with Prader-Willi syndrome</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will give you diet restrictions to follow to control your weight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will assess you for signs of upper airway obstruction, sleep apnoea (where your breathing is interrupted during sleep), or respiratory infection before you start treatment with somatropin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During treatment with somatropin, tell your doctor if you show signs of upper airway obstruction (including starting to snore or worsening of snoring), your doctor will need to examine you and may interrupt treatment with somatropin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During treatment, your doctor will check you for signs of scoliosis, a type of spinal deformity.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During treatment, if you develop a lung infection, tell your doctor so that he can treat the infection.</p><p><strong>Children born small or too light at birth</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you were too small or too light at birth and are aged between 9 and 12&nbsp;years, ask your doctor for specific advice relating to puberty and treatment with this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment should be continued until you have stopped growing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will check your blood sugar and insulin levels before the start of treatment and every year during treatment.</p><p><strong>Other medicines and Omnitrope</strong></p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p>In particular, inform your doctor if you are taking or have recently taken any of the following medicines. Your doctor may need to adjust the dose of Omnitrope or of the other medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicine to treat diabetes,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thyroid hormones,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to control epilepsy (anticonvulsants),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin (a medicine that weakens the immune system after transplantation),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oestrogen taken orally or other sex hormones,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; synthetic adrenal hormones (corticosteroids).</p><p>Your doctor may need to adjust the dose of these medicines or the dose of somatropin.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>You should not use Omnitrope if you are pregnant or trying to become pregnant.<br /><br />Ask your doctor or pharmacist for advice if you are pregnant or breast ‑feeding,. This is because benzyl alcohol can build-up in your body and may cause side effects (called &ldquo;metabolic acidosis&rdquo;).</p><p><strong>Important information about some of the ingredients of Omnitrope</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per ml, i.e. essentially &lsquo;sodium- free&rsquo;.</p><p>Omnitrope 5&nbsp;mg/1.5&nbsp;ml solution for injection:</p><p>This medicine contains 9 mg benzyl alcohol in each ml.<br />Benzyl alcohol may cause allergic reactions.</p><p>Benzyl alcohol has been linked with the risk of severe side effects including breathing problems (called &ldquo;gasping syndrome&rdquo;) in young children.</p><p>Do not give to your newborn baby (up to 4 weeks old), unless recommended by your doctor.</p><p>Ask your doctor or pharmacist for advice if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called &ldquo;metabolic acidosis&rdquo;).</p><p>Because of the presence of benzyl alcohol the medicinal product must not be given to premature babies or neonates. It may cause toxic reactions and allergic reactions in infants and children up to 3 years old.</p><p>Do not use for more than a week in young children (less than 3. years old), unless advised by your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist or nurse has told you. Check with your doctor, nurse or pharmacist if you are not sure.</p><p>The dose depends on your size, the condition for which you are being treated and how well growth hormone works for you. Everyone is different. Your doctor will advise you about your individualised dose of Omnitrope in milligrams (mg) from either your body weight in kilograms (kg) or your body surface area calculated from your height and weight in square metres (m<sup>2</sup>), as well as your treatment schedule. Do not change the dosage and treatment schedule without consulting your doctor.</p><p><strong>The recommended dose is for:</strong></p><p><strong>Children with growth hormone deficiency:</strong></p><p>0.025&ndash;0.035 mg/kg body weight per day or 0.7&ndash;1.0&nbsp;mg/m<sup>2</sup> body surface area per day. Higher doses can be used. When growth hormone deficiency continues into adolescence, Omnitrope should be continued until completion of physical development.</p><p><strong>Children with Turner syndrome:</strong></p><p>0.045&ndash;0.050&nbsp;mg/kg body weight per day or 1.4&nbsp;mg/m<sup>2</sup> body surface area per day.</p><p><strong>Children with chronic renal (kidney) insufficiency:</strong></p><p>0.045&ndash;0.050&nbsp;mg/kg body weight per day or 1.4&nbsp;mg/m<sup>2</sup> body surface area per day. Higher doses may be necessary if the rate of growth is too low. Dosage adjustment may be necessary after 6&nbsp;months of treatment.</p><p><strong>Children with Prader-Willi syndrome:</strong></p><p>0.035&nbsp;mg/kg body weight per day or 1.0&nbsp;mg/m<sup>2</sup> body surface area per day. The daily dosage should not exceed 2.7&nbsp;mg. Treatment should not be used in children who have almost stopped growing after puberty.</p><p><strong>Children born smaller or lighter than expected and with growth disturbance:</strong></p><p>0.035&nbsp;mg/kg body weight per day or 1.0&nbsp;mg/m<sup>2</sup> body surface area per day. It is important to continue treatment until final height is reached. Treatment should be discontinued after the first year if you are not responding or if you have reached your final height and stopped growing.</p><p><strong>Adults with growth hormone deficiency:</strong></p><p>If you continue Omnitrope after treatment during childhood you should start with 0.2&ndash;0.5&nbsp;mg per day.</p><p>This dosage should be gradually increased or decreased according to blood test results as well as clinical response and side effects.</p><p>If your growth hormone deficiency starts during adult life you should start with 0.15&ndash;0.3&nbsp;mg per day. This dosage should be gradually increased according to blood test results as well as clinical response and side effects. The daily maintenance dose seldom exceeds 1.0&nbsp;mg per day. Women may require higher doses than men. Dosage should be monitored every 6 months. Persons above 60&nbsp;years should start with a dose of 0.1&ndash;0.2&nbsp;mg per day which should be slowly increased according to individual requirements. The minimum effective dose should be used. The maintenance dose seldom exceeds 0.5 mg per day. Follow the instructions given to you by your doctor.</p><p><strong>Injecting Omnitrope</strong></p><p>Inject your growth hormone at about the same time every day. Bedtime is a good time because it is easy to remember. It is also natural to have a higher level of growth hormone at night.</p><p>Omnitrope 5&nbsp;mg/1.5&nbsp;ml in a cartridge for SurePal&nbsp;5 is intended for multiple use. It should only be administered with SurePal&nbsp;5, an injection device specifically developed for use with Omnitrope 5&nbsp;mg/1.5&nbsp;ml solution for injection.</p><p>Omnitrope 10&nbsp;mg/1.5&nbsp;ml in a cartridge for SurePal&nbsp;10 is intended for multiple use. It should only be administered with SurePal&nbsp;10, an injection device specifically developed for use with Omnitrope 10&nbsp;mg/1.5&nbsp;ml solution for injection.</p><p>Omnitrope is intended for subcutaneous use. This means that it is injected through a short injection needle into the fatty tissue just under your skin. Most people do their injections into their thigh or their bottom. Do your injection in the place you have been shown by your doctor. Fatty tissue of the skin can shrink at the site of injection. To avoid this, use a slightly different place for your injection each time. This gives your skin and the area under your skin time to recover from one injection before it gets another one in the same place.</p><p>Your doctor should have already shown you how to use Omnitrope. Always inject Omnitrope exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p><strong>How to inject Omnitrope</strong></p><p>The following instructions explain how to inject Omnitrope yourself. Please read the instructions carefully and follow them step by step. Your doctor will show you how to inject Omnitrope. Do not attempt to inject unless you are sure you understand the procedure and requirements for the injection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Omnitrope is given as an injection under the skin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carefully inspect the solution before injecting it and use only if clear and colourless.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change the injection sites to minimise the risk of local lipoatrophy (local reduction of fatty tissue under the skin).</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:368px"><p><strong>Preparation</strong></p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p>Collect necessary items before you begin:</p></td><td rowspan="3" style="vertical-align:top; width:116px"><p><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_2" o:spid="_x0000_i1027" type="#_x0000_t75"
   alt="Description: Omnitrope Bild 1 new" style='width:54pt;height:50.5pt;
   visibility:visible;mso-wrap-style:square' o:bordertopcolor="black"
   o:borderleftcolor="black" o:borderbottomcolor="black" o:borderrightcolor="black">
   <v:imagedata src="file:///C:/Users/ALLUWMU1/AppData/Local/Temp/4/msohtmlclip1/01/clip_image001.png"
    o:title=" Omnitrope Bild 1 new"/>
   <w:bordertop type="single" width="4"/>
   <w:borderleft type="single" width="4"/>
   <w:borderbottom type="single" width="4"/>
   <w:borderright type="single" width="4"/>
  </v:shape><![endif]--><img width="73" height="69" alt="Description: Omnitrope Bild 1 new" src="file:///C:/Users/ALLUWMU1/AppData/Local/Temp/4/msohtmlclip1/01/clip_image002.jpg" /></p></td></tr><tr><td style="vertical-align:top; width:368px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a cartridge with Omnitrope solution for injection.</p></td></tr><tr><td style="vertical-align:top; width:368px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SurePal, an injection device specifically developed for use with Omnitrope solution for injection (not supplied in the pack; see Instructions for Use provided with SurePal).</p></td></tr><tr><td style="vertical-align:top; width:368px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a pen needle for subcutaneous injection.</p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;cleansing swabs (not supplied in the pack).</p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p>Wash your hands before you continue with the next steps.</p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p>&nbsp;</p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p><strong>Injecting Omnitrope</strong></p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With a cleansing swab, disinfect the rubber membrane of the cartridge.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The contents must be clear and colourless.</p></td><td style="vertical-align:top; width:116px"><p><!--[if gte vml 1]><v:shape id="_x0000_s1026" type="#_x0000_t75"
   style='position:absolute;margin-left:-67.4pt;margin-top:-.5pt;width:49.5pt;
   height:50.45pt;z-index:-251656704;visibility:visible;mso-wrap-edited:f;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   wrapcoords="-176 0 -176 21427 21600 21427 21600 0 -176 0" fillcolor="window">
   <v:imagedata src="file:///C:/Users/ALLUWMU1/AppData/Local/Temp/4/msohtmlclip1/01/clip_image003.wmz"
    o:title=""/>
   <w:wrap type="tight"/>
   <w:anchorlock/>
  </v:shape><![if gte mso 9]><o:OLEObject Type="Embed" ProgID="Word.Picture.8"
   ShapeID="_x0000_s1026" DrawAspect="Content" ObjectID="_1656411372">
  </o:OLEObject>
 <![endif]><![endif]--><img width="66" height="67" src="file:///C:/Users/ALLUWMU1/AppData/Local/Temp/4/msohtmlclip1/01/clip_image004.png" /></p></td></tr><tr><td style="vertical-align:top; width:368px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insert the cartridge into the pen for injection. Follow the Instructions for Use of the pen injector. To setup the pen dial the dose.</p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Select the site of injection. The best sites for injection are tissues with a layer of fat between skin and muscle, such as the thigh or belly (except the navel or waistline).</p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure you inject at least 1&nbsp;cm from your last injection site and that you change the places where you inject, as you have been taught.</p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before you make an injection, clean your skin well with an alcohol swab. Wait for the area to dry.</p></td><td style="vertical-align:top; width:116px"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_1" o:spid="_x0000_i1026" type="#_x0000_t75" alt="Description: 33mg-04-clean"
   style='width:50.5pt;height:50.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ALLUWMU1/AppData/Local/Temp/4/msohtmlclip1/01/clip_image005.png"
    o:title=" 33mg-04-clean"/>
  </v:shape><![endif]--><img width="67" height="67" alt="Description: 33mg-04-clean" src="file:///C:/Users/ALLUWMU1/AppData/Local/Temp/4/msohtmlclip1/01/clip_image006.png" /></p></td></tr><tr><td style="vertical-align:top; width:368px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insert the needle into the skin in the way your doctor has taught you.</p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p>&nbsp;</p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p><strong>After injecting</strong></p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After injection, press the injection site with a small bandage or sterile gauze for several seconds. Do not massage the injection site.</p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the needle off the pen using the outer needle cap, and discard the needle. This will keep the Omnitrope<sup> </sup>solution sterile and prevent leaking. It will also stop air going back into the pen and the needle clogging up. Do not share your needles. Do not share your pen.</p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leave the cartridge in the pen, put the cap on the pen, and store it in the refrigerator.</p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:368px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The solution should be clear after removal from the refrigerator. <strong>Do not use if the solution is cloudy or contains particles.</strong></p></td><td style="vertical-align:top; width:116px"><p>&nbsp;</p></td></tr></tbody></table><p><strong>If you use more Omnitrope than you should</strong></p><p>If you inject much more than you should, contact your doctor or pharmacist as soon as possible. Your blood sugar level could fall too low and later rise too high. You might feel shaky, sweaty, sleepy or &ldquo;not yourself&rdquo;, and you might faint.</p><p><strong>If you forget to use Omnitrope</strong></p><p>Do not use a double dose to make up for a forgotten dose. It is best to use your growth hormone regularly. If you forget to use a dose, have your next injection at the usual time the next day. Keep a note of any missed injections and tell your doctor at your next check-up.</p><p><strong>If you stop using Omnitrope</strong></p><p>Ask for advice from your doctor before you stop using Omnitrope.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The very common and common side effects in adults may start within the first months of treatment and may either stop spontaneously or if your dose is reduced.</p><p>&nbsp;</p><p><strong>Very common side effects (may affect more than 1 in 10 people) include:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water retention (which shows as puffy fingers or swollen ankles, for a short time at the start of treatment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reddening, itchiness or pain at the injection site</p><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10 people) include:</strong></p><p><strong>&nbsp;</strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raised itchy bumps on the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness/tingling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stiffness in the arms and legs, muscle pain</p><p><strong>In adults</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain or burning sensation in the hands or underarms (known as Carpal Tunnel syndrome)</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 patients) include:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast enlargement (gynaecomastia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching</p><p>&nbsp;</p><p><strong>Rare side effects (may affect up to 1 in 1,000 patients) include:</strong></p><p><strong>&nbsp;</strong></p><p><strong>In children</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leukaemia (This has been reported in a small number of growth hormone deficiency patients, some of whom have been treated with somatropin. However, there is no evidence that leukaemia incidence is increased in growth hormone recipients without predisposing factors.)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased intracranial pressure (which causes symptoms, such as strong headache, visual disturbances or vomiting)</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Type 2 diabetes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A decrease in the levels of the hormone Cortisol in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Facial swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypothyroidism</p><p>&nbsp;</p><p><strong>In adults</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased intracranial pressure (which causes symptoms such as strong headache, visual disturbances or vomiting)</p><p>&nbsp;</p><p>Formation of antibodies to the injected growth hormone but these do not seem to stop the growth hormone from working.</p><p>&nbsp;</p><p>The skin around the injection area can get uneven or lumpy, but this should not happen if you inject in a different place each time.</p><p>&nbsp;</p><p>There have been rare cases of sudden death in patients with Prader-Willi syndrome. However, no link has been made between these cases and treatment with Omnitrope.</p><p>&nbsp;</p><p>Slipped capital femoral epiphysis and Legg-Calv&eacute;-Perthes disease may be considered by your doctor if discomfort or pain in the hip or knee is experienced whilst being treated with Omnitrope.</p><p>&nbsp;</p><p>Other possible side effects related to your treatment with growth hormone may include the following:</p><p>&nbsp;</p><p>You (or your child) may experience a high blood sugar or reduced levels of thyroid hormone. This can be tested by your doctor and if necessary your doctor will prescribe the adequate treatment. Rarely, an inflammation of the pancreas has been reported in patients treated with growth hormone.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store and transport refrigerated (2&deg;C&ndash;8&deg;C).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After the first injection, the cartridge should remain in the pen injector and has to be stored in a refrigerator (2&deg;C&ndash;8&deg;C) and only used for a maximum of 28&nbsp;days.</p><p>Do not use Omnitrope if you notice that the solution is cloudy.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Omnitrope 5&nbsp;mg/1.5&nbsp;ml contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance of Omnitrope is somatropin.</p><p>Each ml of solution contains 3.3&nbsp;mg of somatropin (corresponding to 10&nbsp;IU)</p><p>One cartridge contains 5.0&nbsp;mg (corresponding to 15&nbsp;IU) of somatropin in 1.5&nbsp;ml.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>disodium hydrogen phosphate heptahydrate</p><p>sodium dihydrogen phosphate dihydrate</p><p>mannitol</p><p>poloxamer 188</p><p>benzyl alcohol</p><p>water for injections</p><p><strong>What Omnitrope 10&nbsp;mg/1.5&nbsp;ml contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance of Omnitrope is somatropin.</p><p>Each ml of solution contains 6.7&nbsp;mg of somatropin (corresponding to 20&nbsp;IU)</p><p>One cartridge contains 10.0&nbsp;mg (corresponding to 30&nbsp;IU) of somatropin in 1.5&nbsp;ml.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>disodium hydrogen phosphate heptahydrate</p><p>sodium dihydrogen phosphate dihydrate</p><p>glycine</p><p>poloxamer 188</p><p>phenol</p><p>water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Omnitrope is a clear and colourless solution for injection.
Omnitrope 5 mg/1.5 ml solution for injection is for use in SurePal 5 only.
Omnitrope 10 mg/1.5 ml solution for injection is for use in SurePal 10 only.
Pack sizes of 1, 5 or 10.
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Sandoz GmbH</p><p>Biochemiestr. 10</p><p>A-6250 Kundl</p><p>Austria</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Sandoz&nbsp;GmbH</p><p>Biochemiestr. 10</p><p>A-6336&nbsp;Langkampfen</p><p>Austria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">أومنيتروب عبارة عن هرمون نمو بشري مَأْشوب (يُدعى أيضًا سوماتروبين). ويتسم بنفس بنية هرمون النمو البشري الطبيعي اللازم توفره لنمو العظام والعضلات. كما أنه يساعد على نمو أنسجة الدهون والعضلات بالقدر المناسب. وهو مَأْشوب بمعنى أنه ليس مصنوعًا من الأنسجة البشرية أو الحيوانية.</p><p dir="RTL">&nbsp;</p><p><strong>بالنسبة للأطفال، يُستخدم عقار أومنيتروب لعلاج اضطرابات النمو التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت لا تنمو بالمعدل المناسب وليس لديك ما يكفي من هرمون النمو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مصابة بمتلازمة تيرنر. متلازمة تيرنر هي اضطراب وراثي في الفتيات يُمكن له أن يؤثر على النمو &ndash; سيكون طبيبكِ قد أخبركِ إذا كنتِ مصابة بهذه المتلازمة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من قصور مزمن بوظائف الكُلى. عندما تعجز الكُلى عن أداء وظائفها بشكل طبيعي، يُمكن لذلك أن يؤثر على النمو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من صغر الحجم عند الولادة أو انخفاض الوزن الشديد عند الولادة. يمكن أن يساعد هرمون النمو على زيادة الطول إذا لم يكن الشخص قادرًا على الوصول إلى مستوى النمو الطبيعي أو الاستمرار فيه بعمر 4 أعوام أو أكثر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمتلازمة برادر-ڤيلي (اضطراب كروموسومي). سيساعد هرمون النمو على زيادة الطول إذا كان الشخص لا يزال في طور النمو، كما أنه سيحسن تركيب الجسم. ستنخفض الدهون الزائدة وستتحسن الكتلة العضلية المتناقصة.</p><p dir="RTL">&nbsp;</p><p><strong>بالنسبة للبالغين، يُستخدم عقار أومنيتروب فيما يلي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج الأشخاص الذين يعانون من نقص واضح في هرمون النمو. يمكن أن يبدأ ذلك إما في فترة البلوغ أو أن يكون مستمرًا معهم من فترة الطفولة.</p><p dir="RTL">إذا كنت قد تلقيت العلاج بعقار أومنيتروب لعلاج نقص هرمون النمو أثناء فترة الطفولة، فستعيد اختبار حالة هرمون النمو بعد اكتمال النمو. وإذا تم التأكد من وجود نقص شديد في هرمون النمو، فسيقترح طبيبك أن تواصل العلاج بعقار أومنيتروب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا يُعطيك هذا الدَّواء إلا طبيب لديه خبرة في العلاج بهرمون النمو وأن يكون هذا الطبيب قد تأكد من تشخيصك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم عقار أومنيتروب في الحالات التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من حساسية (فرط حساسية) تجاه سوماتروبين أو تجاه أيٍّ من مكونات عقار أومنيتروب الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كنت مصابًا بورم نشط (سرطان). يجب أن تكون الأورام غير نشطة وأن تكون قد أنهيت علاجك المضاد للأورام قبل أن تبدأ العلاج بعقار أومنيتروب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كان عقار أومنيتروب قد وُصف لك لتحفيز النمو ولكن نموك قد توقف بالفعل (إغلاق المشاشية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مريضًا بشكل خطير (مثل المضاعفات التالية لجراحة القلب المفتوح، جراحة بالبطن، إصابة رضحية عارضة، فشل تنفسي حاد، أو ما شابه من حالات مرضية). إذا كنت على وشك الخضوع لعملية جراحية كبرى، أو خضعت بالفعل لعملية جراحية كبرى، أو ستذهب إلى المستشفى لأي سبب من الأسباب، أخبر طبيبك وذكِّر الأطباء الآخرين الذين تُعرض عليهم بأنك تستخدم هرمون النمو.</p><p dir="RTL">&nbsp;</p><p>تحذيرات واحتياطات</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحدث إلى طبيبك قبل استخدام عقار أومنيتروب في الحالات الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع لعلاج تعويضي بالجلوكوكورتيكويدات، فيجب عليك استشارة طبيبك بانتظام؛ إذ قد يستلزم الأمر تعديل جرعة الجلوكوكورتيكويدات الخاصة بك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت معرضًا للإصابة بمرض السُّكَّرِي، فسينبغي لطبيبك مراقبة مستوى السكر في دمك أثناء العلاج بسوماتروبين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض السُّكَّرِي، فيجب عليك مراقبة مستوى السكر في دمك عن كثب أثناء العلاج بسوماتروبين ومناقشة النتائج مع طبيبك لتحديد ما إذا كان من اللازم تغيير جرعتك من الأدوية التي تتناولها لعلاج مرض السُّكَّرِي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد بدء العلاج بسوماتروبين، قد ينبغي لبعض المرضى البدء في تعويض هرمون الغدة الدَّرقية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى علاجًا بهرمونات الغدة الدرقية، فقد يصبح من الضروري تعديل جرعتك من هرمون الغدة الدرقية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ارتفاع الضغط داخل الجمجمة (الذي يسبب أعراضًا من قبيل الصداع الشديد أو اضطرابات الرؤية أو القيء)، فيجب عليك إبلاغ طبيبك بذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعرج في مشيتك أو إذا بدأت تعرج أثناء العلاج بهرمون النمو، فيجب عليك إبلاغ طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى سوماتروبين لعلاج نقص هرمون النمو بعد ورم (سرطان) سابق، يجب أن يتم فحصك بانتظام تحسبًا لمعاودة الورم أو أي سرطان آخر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت من ألم متفاقم بالبطن، يجب عليك إبلاغ طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخبرة محدودة في المرضى ممن تزيد أعمارهم عن 80 عامًا. قد يكون كبار السن أكثر حساسية تجاه مفعول سوماتروبين، وبالتالي قد يكونون أكثر عرضة للإصابة بالآثار الجانبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتسبب عقار أومنيتروب في حدوث التهاب في البنكرياس، مما يسبب ألمًا شديدًا في البطن والظهر. اتصل بطبيبك إذا عانيت أنت أو طفلك من ألم بالمعدة بعد تلقي عقار أومنيتروب.</p><p dir="RTL">&nbsp;</p><p><strong>الأطفال المصابون بقصور مزمن بوظائف الكُلى</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب على طبيبك فحص وظائف الكُلى لديك ومعدل نموك قبل البدء في استخدام سوماتروبين. يجب أن يستمر العلاج الطبي للكُلى. يجب إيقاف العلاج بسوماتروبين عند زرع الكُلى.</p><p dir="RTL">&nbsp;</p><p><strong>الأطفال المصابون بمتلازمة برادر-ڤيلي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيفرض طبيبك قيودًا على نظامك الغذائي لتلتزم بها للتحكم في وزنك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك بتقييمك تحسبًا لوجود علامات لانسداد المسلك الهوائي العلوي، أو انقطاع التنفس أثناء النوم، أو عدوى الجهاز التنفسي قبل أن تبدأ العلاج بسوماتروبين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء فترة العلاج بسوماتروبين، أخبر طبيبك إذا ظهرت عليك علامات انسداد المسلك الهوائي العلوي (بما في ذلك إذا بدأت في الشخير أو إذا تفاقم الشخير)، لأن طبيبك سيحتاج إلى فحصك وقد يوقف علاجك بسوماتروبين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء فترة العلاج، سيفحصك طبيبك للتحقق مما إذا كانت توجد علامات للجنف، وهو نوع من أنواع تشوه العمود الفقري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت أثناء فترة العلاج بعدوى في الرئة، فأخبر طبيبك حتى يتمكن من علاج العدوى.</p><p dir="RTL">&nbsp;</p><p><strong>الأطفال صغيرو الحجم عند الولادة أو ذوو الأوزان المنخفضة للغاية عند الولادة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت من صغيري الحجم عند الولادة أو ذوي الأوزان المنخفضة للغاية عند الولادة وكان عمرك ما بين 9 و12 عامًا، فاستشر طبيبك فيما يتعلق تحديدًا بسن البلوغ والعلاج باستخدام هذا الدَّواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجب مواصلة العلاج إلى أن يتوقف النمو لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك بفحص مستويات الأنسولين والسكر في دمك قبل بدء العلاج وفي كل عام أثناء العلاج.</p><p dir="RTL">&nbsp;</p><p><strong>الأدوية الأخرى وعقار أومنيتروب</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وعلى وجه الخصوص، أخبر طبيبك إذا كنت تتلقى أو تلقيت مؤخرًا أيًّا من الأدوية التَّالية. قد يحتاج طبيبك إلى تعديل جرعتك من عقار أومنيتروب أو الأدوية الأخرى:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج مرض السُّكَّرِي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمونات الغدة الدرقية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية التحكم في الصرع (مضادات التشنج)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين (وهو دواء يُضعِف الجهاز المناعي بعد زرع الأعضاء)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإستروجين الذي يؤخذ عن طريق الفم أو الهرمونات الجنسية الأخرى،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمونات الغدة الكظرية المُخلَّقة (الكورتيكوستيرويدات).</p><p dir="RTL">قد يكون طبيبك بحاجة إلى تعديل جرعتك من هذه الأدوية أو من سوماتروبين.</p><p dir="RTL">&nbsp;</p><p><strong>الحمل والرَّضاعة الطبيعية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يجب ألا تستخدمي عقار أومنيتروب إذا كنتِ حاملًا أو تحاولين الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشيري طبيبكِ أو الصيدلي الخاص بكِ إذا كنتِ حاملًا أو مرضعًا. يرجع هذا إلى أن الكحول البنزيلي قد يتراكم في جسمكِ وقد يُسبب آثارًا جانبية (تُسمى &quot;الحُماض الاستقلابي&quot;).</p><p dir="RTL">&nbsp;</p><p><strong>معلومات هامَّة عن بعض مكونات عقار أومنيتروب:</strong></p><p dir="RTL">يحتوي هذا الدَّواء على أقل من 1 مللي مول من الصوديوم (23 مجم) لكل مللي لتر، أي أنه &quot;خال من الصوديوم&quot; بشكل أساسي. أومنيتروب 5 مجم/ 1.5 مللي لتر محلول للحقن:</p><p dir="RTL">يحتوي هذا الدَّواء على 9 مجم كحول بنزيلي في كل مللي لتر.</p><p dir="RTL">قد يُسبب الكحول البنزيلي تفاعلات حساسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ارتبط الكحول البنزيلي باحتمالية حدوث آثار جانبية شديدة من بينها مشاكل التنفس (تسمى &quot;متلازمة اللهاث&quot;) عند الأطفال الصغار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تعطه لطفلك حديث الولادة (حتى عمر 4 أسابيع)، إلا إذا أوصى طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك أو الصيدلي إذا كنت مصابًا بمرض بالكُلى أو الكبد. يرجع هذا إلى أنه قد تتراكم كميات كبيرة من الكحول البنزيلي في جسمك وقد تُسبب آثارًا جانبية (تُسمى &quot;الحُماض الاستقلابي&quot;).</p><p dir="RTL">نظرًا لوجود كحول بنزيلي بالمنتج الدوائي؛ يجب ألا يُعطى للأطفال المبتسرين أو الأطفال حديثي الولادة. قد يتسبب العقار في تفاعلات سمية وتفاعلات حساسية لدى الرضع والأطفال الذين تصل أعمارهم حتى 3 أعوام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدمه لأكثر من أسبوع للأطفال الصغار (الأصغر من 3 أعوام)، ما لم ينصحك طبيبك أو الصيدلي بذلك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم هذا الدَّواء دائمًا كما أخبرك طبيبك أو الصيدلي أو الممرضة بالضبط. يُرجى مراجعة طبيبك أو الممرضة أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">تتوقف الجرعة على حجمك والحالة المرضية التي تُعالَج منها ومدى فعالية هرمون النمو بالنسبة لك. يختلف كل شخص عن الآخر. سيصف لك طبيبك جرعة مخصصة لك تحديدًا من عقار أومنيتروب بالملليجرام (مجم) إما حسب وزن جسمك بالكيلوجرام (كجم) أو حسب مساحة سطح جسمك المحسوبة من طولك ووزنك بالمتر المربع (م<sup>2</sup>)، بالإضافة إلى جدول العلاج الخاص بك. لا تقم بتغيير الجرعة وجدول العلاج بدون استشارة طبيبك.</p><p dir="RTL">&nbsp;</p><p>الجُرعة المُوصى بها للآتي:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال المصابين بنقص هرمون النمو:</strong></p><p dir="RTL">0.025 - 0.035 مجم/كجم من وزن الجسم في اليوم أو 0.7 - 1.0 مجم/متر مربع من مساحة سطح الجسم في اليوم. يمكن استخدام جرعات أعلى. عندما يستمر نقص هرمون النمو في مرحلة المراهقة، يجب أن يستمر العلاج بعقار أومنيتروب حتى اكتمال النمو البدني.</p><p dir="RTL">&nbsp;</p><p><strong>الطفلات المصابات بمتلازمة تيرنر:</strong></p><p dir="RTL">0.045 - 0.050 مجم/كجم من وزن الجسم في اليوم أو 1.4 مجم/متر مربع من مساحة سطح الجسم في اليوم.</p><p dir="RTL">&nbsp;</p><p><strong>الأطفال المصابين بقصور مزمن بوظائف الكُلى:</strong></p><p dir="RTL">0.045 - 0.050 مجم/كجم من وزن الجسم في اليوم أو 1.4 مجم/متر مربع من مساحة سطح الجسم في اليوم. قد يكون من الضروري استخدام جرعات أعلى إذا كان معدل النمو منخفضًا للغاية. قد يكون من الضروري تعديل الجرعة بعد مرور 6 أشهر من العلاج.</p><p dir="RTL">&nbsp;</p><p><strong>الأطفال المصابين بمتلازمة برادر-ڤيلي:</strong></p><p dir="RTL">0.035 مجم/كجم من وزن الجسم في اليوم أو 1.0 مجم/متر مربع من مساحة سطح الجسم في اليوم. يجب ألا تتجاوز الجرعة اليومية 2.7 مجم. يجب ألا يُستخدم العلاج للأطفال الذين توقف النمو لديهم تقريبًا بعد سن البلوغ.</p><p dir="RTL">&nbsp;</p><p><strong>الأطفال صغيري الحجم عند الولادة أو ذوي الأوزان الأقل من المتوقع عند الولادة ويعانون من اضطراب بالنمو:</strong></p><p dir="RTL">0.035 مجم/كجم من وزن الجسم في اليوم أو 1.0 مجم/متر مربع من مساحة سطح الجسم في اليوم. من المهم مواصلة العلاج إلى أن يتم الوصول إلى الطول النهائي. يجب إيقاف العلاج بعد السنة الأولى إذا كنت لا تستجيب له أو إذا وصلت إلى الطول النهائي وتوقف النمو لديك.</p><p dir="RTL">&nbsp;</p><p><strong>البالغين المصابين بنقص هرمون النمو:</strong></p><p dir="RTL">إذا كنت بصدد مواصلة العلاج بعقار أومنيتروب بعد العلاج به أثناء فترة الطفولة فيجب أن تبدأ بجرعة 0.2 - 0.5 مجم في اليوم. يجب تقليل هذه الجرعة أو زيادتها تدريجيًّا وفقًا لنتائج اختبار الدم بالإضافة إلى الاستجابة السريرية والآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا بدأ نقص هرمون النمو لديك بعد أن أصبحت بالغًا، فيجب أن تبدأ بجرعة 0.15 - 0.3 مجم في اليوم. تجب زيادة هذه الجرعة تدريجيًّا وفقًا لنتائج اختبار الدم بالإضافة إلى الاستجابة السريرية والآثار الجانبية. نادرًا ما تتجاوز جرعة المداومة اليومية 1.0 مجم في اليوم. قد تحتاج السيدات إلى جرعات أعلى من الرجال. تجب مراقبة الجرعة كل 6 أشهر. يجب أن يبدأ الأشخاص الأكبر من 60 عامًا بجرعة قدرها 0.1 - 0.2 مجم في اليوم مع مراعاة زيادتها ببطء وفقًا لاحتياجات كل شخص على حدة. يجب استخدام أقل جرعة فعالة. نادرًا ما تتجاوز جرعة المداومة 0.5 مجم في اليوم. اتبع تعليمات طبيبك.</p><p dir="RTL">&nbsp;</p><p><strong>حقن عقار أومنيتروب</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">احقن هرمون النمو في الوقت نفسه تقريبًا من كل يوم. ويُعد وقت الخلود إلى النوم وقتًا مناسبًا للحقن لأنه من السهل تذكُّره. كما أنه من الطبيعي أن يكون مستوى هرمون النمو أعلى في الليل.</p><p dir="RTL">أومنيتروب 5 ملغم/1.5&nbsp;مل في خرطوشة للاستخدام مع SurePal&nbsp;5 مخصص للاستخدام المتعدد. لا ينبغي إعطاؤه إلا باستخدام SurePal&nbsp;5، جهاز للحقن مطور خصيصًا للاستخدام مع محلول أومنيتروب 5&nbsp;ملغم/1.5&nbsp;مل المعد للحقن.</p><p dir="RTL">أومنيتروب 10 ملغم/1.5&nbsp;مل في خرطوشة للاستخدام مع SurePal&nbsp;10 مخصص للاستخدام المتعدد. لا ينبغي إعطاؤه إلا باستخدام SurePal&nbsp;10، جهاز للحقن مطور خصيصًا للاستخدام مع محلول أومنيتروب 10&nbsp;ملغم/1.5&nbsp;مل المعد للحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقار أومنيتروب مخصص للحقن أسفل الجلد. وهذا يعني أنه يُحقَن داخل النَّسيج الدُّهني تحت الجلد مباشرة بواسطة إبرة حقن قصيرة. معظم الأشخاص يقومون بالحقن في الفخذ أو المؤخرة. قم بالحقن في الموضع الذي وضحه لك طبيبك. يمكن أن تتقلص الأنسجة الدهنية للجلد في موضع الحقن. ولتجنب ذلك، اختر موضعًا مختلفًا قليلًا في كل مرة حقن. يمنح ذلك الجلد والمنطقة الموجودة تحته وقتًا للتعافي من الحقنة التي تم أخذها قبل أخذ حقنة أخرى في الموضع نفسه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المفترض أن يكون طبيبك قد أوضح لك بالفعل كيفية استخدام عقار أومنيتروب. احقن عقار أومنيتروب دائمًا كما أخبرك طبيبك بالضبط. عليك مراجعة طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">&nbsp;</p><p><strong>كيفية حقن عقار أومنيتروب</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">توضح التعليمات التالية كيفية حقن نفسك بعقار أومنيتروب. يُرجى قراءة التعليمات بعناية واتباعها خطوة بخطوة. سيُريك طبيبك كيفية حقن عقار أومنيتروب. لا تحاول القيام بالحقن إلا بعدما تتأكد من أنك فهمت إجراء الحقن ومتطلباته.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُعطى عقار أومنيتروب في هيئة حَقْن تحت الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفحص المحلول بعناية قبل حقنه ولا تستخدمه إلا إذا كان صافيًا وعديم اللون.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احرص على تغيير مواضع الحقن لتقليل احتمالية حدوث الضمور الشحمي الموضعي (انخفاض موضعي بالأنسجة الدهنية تحت الجلد).</p><p dir="RTL">&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_s1027" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:44.9pt;margin-top:4.55pt;width:48.6pt;
 height:49.2pt;z-index:251659776'>
 <v:imagedata src="file:///C:/Users/abulase1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="65" height="66" src="file:///C:/Users/abulase1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg" /><strong>التَّحضير</strong></p><p dir="RTL">أحضر المواد اللازمة قبل البدء:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خرطوشة عقار أومنيتروب محلول للحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SurePal ،جهاز حقن تم تصنيعه خصيصًا للاستخدام مع عقار أومنيتروب محلول للحقن (غير مرفق مع العبوة؛ انظر &quot;تعليمات الاستخدام&quot; المرفقة مع SurePal).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبرة قلم للحقن تحت الجلد (غير مرفقة مع العبوة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مسحتي تنظيف (غير مرفقتين مع العبوة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">اغسل يديك قبل المتابعة إلى الخطوات التالية.</p><p dir="RTL">&nbsp;</p><p><!--[if gte vml 1]><v:rect id="_x0000_s1028"
 style='position:absolute;left:0;text-align:left;margin-left:31.2pt;
 margin-top:15.9pt;width:58.8pt;height:49pt;z-index:251660800' o:allowincell="f"
 filled="f" stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1028' inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL style='text-align:right;line-height:49.0pt;
    mso-pagination:widow-orphan;mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other;
    direction:rtl;unicode-bidi:embed'><b><span dir=LTR><v:shape id="_x0000_i1025"
     type="#_x0000_t75" style='width:48pt;height:49.5pt'>
     <v:imagedata src="file:///C:/Users/abulase1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png"
      o:title=""/>
    </v:shape></span></b><span dir=LTR style='font-size:12.0pt'><o:p></o:p></span></p>
    <p class=MsoNormal><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:rect><![endif]--><img width="82" height="69" alt="Text Box:  

" src="file:///C:/Users/abulase1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.png" /><strong>حقن عقار أومنيتروب</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقِّم غشاء الخرطوشة المطاطي باستخدام مسحة تنظيف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تكون المحتويات صافية وعديمة اللون.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدخل الخرطوشة في قلم الحقن. اتبع &quot;تعليمات الاستخدام&quot; الخاصة بحاقن القلم. لإعداد القلم أدر قرص الجرعة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدد موضع الحقن. أفضل مواضع الحقن هي الأنسجة التي بها طبقة دهون بين الجلد والعضلات، مثل الفخذ أو البطن (باستثناء السرة أو الخصر).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأكد من قيامك بالحقن في موضع يبعد 1 سم على الأقل عن الموضع الذي تم الحقن فيه آخر مرة، ومن تغيير مواضع الحقن، حسب التعليمات التي أُعطيت لك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:rect
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:87.35pt;margin-top:4.4pt;width:62.8pt;height:49pt;text-indent:0;
 z-index:251654656;mso-position-horizontal-relative:page' o:allowincell="f"
 filled="f" stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1026' inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:rect><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><!--[if gte vml 1]><v:shape
     id="_x0000_i1026" type="#_x0000_t75" style='width:49.5pt;height:49.5pt'>
     <v:imagedata src="file:///C:/Users/abulase1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.png"
      o:title=""/>
    </v:shape><![endif]--><img width="66" height="66" src="file:///C:/Users/abulase1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.jpg" /></p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>قبل الحقن، احرص على تنظيف الجلد جيدًا بمسحة كحول. انتظر حتى تجف المنطقة.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدخل الإبرة في الجلد بالطريقة التي أوضحها لك طبيبك.</p><p dir="RTL">&nbsp;</p><p><strong>بعد الحقن</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد الحقن، اضغط على موضع الحقن بضمادة صغيرة أو قطعة شاش معقمة لعدة ثوانٍ. لا تقم بتدليك موضع الحقن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزع الإبرة من القلم باستخدام غطاء الإبرة الخارجي، ثم تخلص منها. فهذا من شأنه أن يحافظ على محلول أومنيتروب معقمًا ويحول دون تسربه. كما أنه سيحول دون رجوع الهواء إلى القلم وانسداد الإبرة. لا تشارك الإبر الخاصة بك مع أي شخص. ولا تشارك قلمك مع أي شخص.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اترك الخرطوشة في القلم، وضع الغطاء على القلم، وضع القلم في الثلاجة.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>يجب أن يكون المحلول صافيًا بعد إخراجه من الثلاجة. <strong>لا تستخدم المحلول إذا كان غائمًا أو يحتوي على جسيمات.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p><strong>إذا استخدمت كمية أكثر مما يجب من عقار أومنيتروب</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا حقنت مقدارًا أكبر بكثير مما يجب، فاتصل بطبيبك أو الصيدلي بأسرع ما يمكن. قد ينخفض مستوى السكر في دمك بشدة ثم يرتفع لاحقًا بشدة. قد ترتعد، أو تتعرق، أو تشعر بالنعاس، أو بأنك &quot;لست على طبيعتك&quot;، وقد يُغمى عليك.</p><p dir="RTL">&nbsp;</p><p><strong>إذا أغفلت استخدام عقار أومنيتروب</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا تستخدم جرعة مضاعفة لتعويض جرعة نسيتها. من الأفضل أن تستخدم هرمون النمو بانتظام. إذا نسيت استخدام جرعة، فخذ الحقنة التالية في الموعد المعتاد من اليوم التالي. دوِّن أي حقن فائتة وأخبر طبيبك في موعد الفحص التالي.</p><p dir="RTL">&nbsp;</p><p><strong>إذا توقفت عن استخدام عقار أومنيتروب</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">استشر طبيبك قبل التوقف عن استخدام عقار أومنيتروب.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع. قد تبدأ الآثار الجانبية الشائعة جدًّا والشائعة عند البالغين في غضون الأشهر الأولى من العلاج وقد تتوقف إما من تلقاء نفسها أو إذا تم تقليل الجرعة.</p><p dir="RTL">&nbsp;</p><p><strong>الآثار الجانبية الشائعة جدًّا (قد تُؤثر على أكثر من شخص واحد من بين كل 10&nbsp;أشخاص) تشمل:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألمًا بالمفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس الماء (الذي يتمثل في انتفاخ الأصابع أو تورم الكاحلين، لفترة قصيرة عند بدء العلاج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرارًا أو حكة أو ألمًا في موضع الحقن</p><p dir="RTL">&nbsp;</p><p><strong>الآثار الجانبية الشائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص) تشمل:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كتلًا بارزة ومثيرة للحكة بالجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفحًا جلديًّا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خدرًا/ وخزًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبسًا في الذراعين والساقين، ألمًا عضليًّا</p><p>&nbsp;</p><p><strong>في البالغين</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألمًا أو إحساسًا بالحُرْقة في اليدين أو الإبطين (تُعرف بمتلازمة النفق الرسغي)</p><p dir="RTL">&nbsp;</p><p><strong>الآثار الجانبية غير الشائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص) تشمل:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تَضخُّم الثدي (تثدِّي الرجال)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">&nbsp;</p><p><strong>الآثار الجانبية النادرة (قد تؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص) تشمل:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في الأطفال</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الدم (تم الإبلاغ عن حدوث ذلك في عدد قليل من مرضى نقص هرمون النمو، بعضهم عولِج بسوماتروبين. ولكن لا يوجد دليل على أن نسبة حدوث سرطان الدم تزيد لدى الأشخاص الذين يتلقون هرمون النمو ممن ليست لديهم عوامل مُهيئة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الضغط داخل الجمجمة (الذي يسبب أعراضًا من قبيل الصداع الشديد أو اضطرابات الرؤية أو القيء)</p><p dir="RTL">&nbsp;</p><p><strong>غير معروفة (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة):</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السكري من النوع &quot;2&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات هرمون الكورتيزول في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور الغدة الدَّرقية</p><p dir="RTL">&nbsp;</p><p><strong>في البالغين</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الضغط داخل الجمجمة (الذي يسبب أعراضًا من قبيل الصداع الشديد أو اضطرابات الرؤية أو القيء)</p><p dir="RTL">&nbsp;</p><p dir="RTL">تكوُّن أجسام مضادة لهرمون النمو المحقون ولكن لا يبدو أنها توقف مفعول هرمون النمو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عدم استواء الجلد المحيط بموضع الحقن أو تكتله، إلا أنه ليس من المفترض أن يحدث ذلك إذا قمت بالحقن في موضع مختلف في كل مرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كانت هناك حالات نادرة من الوفاة المفاجئة بين المرضى المصابين بمتلازمة برادر-ڤيلي. ولكن لم يتبين وجود علاقة بين هذه الحالات وبين العلاج بعقار أومنيتروب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يضع طبيبك في اعتباره احتمالية إصابتك بانزلاق مشاش رأس عظمة الفخذ ومرض ليغ-كالڤيه-بيرثيز إذا شعرت بانزعاج أو ألم في مفصل الورك أو الركبة أثناء العلاج بعقار أومنيتروب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تشمل الآثار الجانبية المحتملة الأخرى المتعلقة بالعلاج بهرمون النمو ما يلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تعاني (أو يعاني طفلك) من ارتفاع نسبة السكر في الدم أو انخفاض مستويات هرمون الغدة الدرقية. يمكن لطبيبك أن يفحص ذلك وسيصف لك العلاج المناسب إذا لزم الأمر. تم في حالات نادرة الإبلاغ عن حدوث التهاب في البنكرياس في المرضى الذين عُولجوا بهرمون النمو.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;يُحفظ بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصَّلاحية المدون على الملصق والعبوة الكرتونية بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُخزَّن ويُنقَل مُبَرَّدًا (عند 2 ‑ 8 درجات مئوية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تعرضه للتجميد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُخزَّن داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد أول مرة حقن، يجب أن تبقى الخرطوشة في حاقن القلم ويجب تخزينها في الثلاجة (عند 2 - 8 درجات مئوية) واستخدامها فقط خلال 28 يومًا كحد أقصى.</p><p dir="RTL">لا تستخدم عقار أومنيتروب إذا لاحظت أنَّ المحلول غائم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّالة في عقار أومنيتروب هي سوماتروبين.</p><p dir="RTL">يحتوي كل مللي لتر من المحلول على 3.3 مجم سوماتروبين (ما يُعادل 10 وحدات دولية) تحتوي الخرطوشة الواحدة على 5.0 مجم (ما يُعادل 15 وحدة دولية) سوماتروبين في 1.5 مللي لتر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">سباعي هيدرات فوسفات الهيدروجين ثنائي الصوديوم ثنائي هيدرات فوسفات ثنائي هيدروجين الصوديوم مانيتول</p><p dir="RTL">بولوكسامير 188 كحول بنزيلي ماء للحقن</p><p dir="RTL">&nbsp;</p><p>محتويات عقار أومنيتروب 10 مجم/1.5 مللي لتر</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّالة في عقار أومنيتروب هي سوماتروبين.</p><p dir="RTL">يحتوي كل مللي لتر من المحلول على 6.7 مجم سوماتروبين (ما يُعادل 20 وحدة دولية)</p><p dir="RTL">تحتوي الخرطوشة الواحدة على 10.0 مجم (ما يُعادل 30 وحدة دولية) سوماتروبين في 1.5 مللي لتر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">سباعي هيدرات فوسفات الهيدروجين ثنائي الصوديوم ثنائي هيدرات فوسفات ثنائي هيدروجين الصوديوم جلايسين</p><p dir="RTL">بولوكسامير 188 فينول</p><p dir="RTL">ماء للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp; أومنيتروب هو محلول صافٍ عديم اللون معد للحقن.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; محلول أومنيتروب 5&nbsp;ملغم/1.5&nbsp;مل المعد للحقن يُستخدم فقط مع SurePal&nbsp;5.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; محلول أومنيتروب 10&nbsp;ملغم/1.5&nbsp;مل المعد للحقن يُستخدم فقط مع SurePal&nbsp;10.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; تحتوي العبوة على 1 أو 5 أو 10.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; قد لا تتوفر جميع الأحجام في السوق.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك حق التسويق</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">شركة ساندوز المحدودة، 10 بيوكيميشتراسه A-6250 كوندل، النمسا</p><p dir="RTL">&nbsp;</p><p><strong>جهة التصنيع</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">شركة ساندوز المحدودة، 10 بيوكيميشتراسه</p><p dir="RTL">A-6336 لانجكامبفين، النمسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Omnitrope 5 mg/1.5 ml solution for injection
Omnitrope 10 mg/1.5 ml solution for injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Omnitrope 5 mg/1.5 ml solution for injection
Each ml of solution contains 3.3 mg of somatropin* (corresponding to 10 IU)
One cartridge contains 1.5 ml corresponding to 5 mg somatropin* (15 IU).
Excipient(s) with known effect:
One ml contains 9 mg benzyl alcohol.
Omnitrope 10 mg/1.5 ml solution for injection
Each ml of solution contains 6.7 mg of somatropin* (corresponding to 20 IU)
One cartridge contains 1.5 ml corresponding to 10 mg somatropin* (30 IU).
* produced in Escherichia coli by recombinant DNA technology.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection in a cartridge for SurePal 5, SurePal 10.
The solution is clear and colourless.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Infants, children and adolescents</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth disturbance due to insufficient secretion of growth hormone (growth hormone deficiency, GHD).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth disturbance associated with Turner syndrome.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth disturbance associated with chronic renal insufficiency.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth disturbance (current height standard deviation score (SDS) &lt;&nbsp;‑2.5 and parental adjusted height SDS&nbsp;&lt;&nbsp;‑1) in short children/adolescents born small for gestational age (SGA), with a birth weight and/or length below ‑2&nbsp;standard deviation (SD), who failed to show catch-up growth (height velocity (HV) SDS &lt;&nbsp;0 during the last year) by 4&nbsp;years of age or later.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing.</p><p><strong>Adults</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Replacement therapy in adults with pronounced growth hormone deficiency.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Adult onset:</em> Patients who have severe growth hormone deficiency associated with multiple hormone deficiencies as a result of known hypothalamic or pituitary pathology, and who have at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo an appropriate dynamic test in order to diagnose or exclude a growth hormone deficiency.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Childhood onset:</em> Patients who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes. Patients with childhood onset GHD should be re-evaluated for growth hormone secretory capacity after completion of longitudinal growth. In patients with a high likelihood for persistent GHD, i.e. a congenital cause or GHD secondary to a hypothalamic-pituitary disease or insult, an insulin-like growth factor-I (IGF-I) SDS&nbsp;&lt;&nbsp;‑2 off growth hormone treatment for at least 4 weeks should be considered sufficient evidence of profound GHD.</p><p>All other patients will require IGF-I assay and one growth hormone stimulation test</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Diagnosis and therapy with somatropin should be initiated and monitored by physicians who are appropriately qualified and experienced in the diagnosis and management of patients with growth disorders.</p><p><u>Posology</u></p><p><u>Paediatric population</u></p><p>The posology and administration schedule should be individualised.</p><p>Growth disturbance due to insufficient secretion of growth hormone in paediatric patients</p><p>Generally a dose of 0.025&nbsp;‑&nbsp;0.035&nbsp;mg/kg body weight per day or 0.7&nbsp;‑&nbsp;1.0&nbsp;mg/m<sup>2</sup> body surface area per day is recommended. Even higher doses have been used.</p><p>Where childhood onset GHD persists into adolescence, treatment should be continued to achieve full somatic development (e.g. body composition, bone mass). For monitoring, the attainment of a normal peak bone mass defined as a T score&nbsp;&gt;&nbsp;-1 (i.e. standardized to average adult peak bone mass measured by dual energy X-ray absorptiometry taking into account sex and ethnicity) is one of the therapeutic objectives during the transition period. For guidance on dosing see adult section below.</p><p>Prader-Willi syndrome, for improvement of growth and body composition in paediatric patients</p><p>Generally a dose of 0.035&nbsp;mg/kg body weight per day or 1.0&nbsp;mg/m<sup>2</sup> body surface area per day is recommended. Daily doses of 2.7&nbsp;mg should not be exceeded. Treatment should not be used in paediatric patients with a growth velocity less than 1&nbsp;cm per year and near closure of epiphyses.</p><p>Growth disturbance due to Turner syndrome</p><p>A dose of 0.045&nbsp;‑&nbsp;0.050&nbsp;mg/kg body weight per day or 1.4&nbsp;mg/m<sup>2</sup> body surface area per day is recommended.</p><p>Growth disturbance in chronic renal insufficiency</p><p>A dose of 0.045&nbsp;‑&nbsp;0.050&nbsp;mg/kg body weight per day (1.4&nbsp;mg/m<sup>2</sup> body surface area per day) is recommended. Higher doses may be needed if growth velocity is too low. A dose correction can be needed after six months of treatment (see section&nbsp;4.4).</p><p>Growth disturbance in short children/adolescents born small for gestational age (SGA)</p><p>A dose of 0.035&nbsp;mg/kg body weight per day (1&nbsp;mg/m<sup>2</sup> body surface area per day) is usually recommended until final height is reached (see section&nbsp;5.1). Treatment should be discontinued after the first year of treatment if the height velocity SDS is below +&nbsp;1. Treatment should be discontinued if height velocity is &lt;&nbsp;2&nbsp;cm/year and, if confirmation is required, bone age is &gt;&nbsp;14&nbsp;years (girls) or &gt;&nbsp;16&nbsp;years (boys), corresponding to closure of the epiphyseal growth plates.</p><p>Dose recommendations in paediatric patients</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td><p>Indication</p></td><td style="vertical-align:top"><p>mg/kg body weight dose per day</p></td><td style="vertical-align:top"><p>mg/m&sup2; body surface area dose per day</p></td></tr><tr><td style="vertical-align:top"><p>Growth hormone deficiency</p></td><td style="vertical-align:top"><p>0.025&nbsp;‑&nbsp;0.035</p></td><td style="vertical-align:top"><p>0.7&nbsp;‑&nbsp;1.0</p></td></tr><tr><td style="vertical-align:top"><p>Prader-Willi syndrome</p></td><td style="vertical-align:top"><p>0.035</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p>Turner syndrome</p></td><td style="vertical-align:top"><p>0.045&nbsp;‑&nbsp;0.050</p></td><td style="vertical-align:top"><p>1.4</p></td></tr><tr><td style="vertical-align:top"><p>Chronic renal insufficiency</p></td><td style="vertical-align:top"><p>0.045&nbsp;‑&nbsp;0.050</p></td><td style="vertical-align:top"><p>1.4</p></td></tr><tr><td style="vertical-align:top"><p>Children/adolescents born small for gestational age (SGA)</p></td><td><p>0.035</p></td><td><p>1.0</p></td></tr></tbody></table><p><u>Growth hormone deficient adult patients</u></p><p>In patients who continue growth hormone therapy after childhood GHD, the recommended dose to restart is 0.2&nbsp;&ndash;&nbsp;0.5&nbsp;mg per day. The dose should be gradually increased or decreased according to individual patient requirements as determined by the IGF-I concentration.</p><p>In adults with adult-onset GHD, therapy should start with a low dose, 0.15&nbsp;‑&nbsp;0.3&nbsp;mg per day. The dose should be gradually increased according to individual patient requirements as determined by the IGF-I concentration.</p><p>In both cases treatment goal should be insulin-like growth factor (IGF-I) concentrations within 2&nbsp;SDS from the age corrected mean. Patients with normal IGF-I concentrations at the start of the treatment should be administered growth hormone up to an IGF-I level into the upper range of normal, not exceeding the 2&nbsp;SDS. Clinical response and side effects may also be used as guidance for dose titration. It is recognized that there are patients with GHD who do not normalize IGF-I levels despite a good clinical response, and thus do not require dose escalation. The maintenance dose rarely exceeds 1.0&nbsp;mg per day. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are over-treated. The accuracy of the growth hormone dose should therefore be controlled every 6&nbsp;months. As normal physiological growth hormone production decreases with age, dose requirements may be reduced.</p><p><u>Special populations</u></p><p><em>Elderly</em></p><p>In patients above 60&nbsp;years, therapy should start with a dose of 0.1&nbsp;-&nbsp;0.2&nbsp;mg per day and should be slowly increased according to individual patient requirements. The minimum effective dose should be used. The maintenance dose in these patients seldom exceeds 0.5&nbsp;mg per day.</p><p><u>Method of administration</u></p><p>The injection should be given subcutaneously and the site varied to prevent lipoatrophy.</p><p>For instructions for use and handling see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Somatropin must not be used when there is any evidence of activity of a tumour. Intracranial tumours must be inactive and anti-tumour therapy must be completed prior to starting GH therapy. Treatment should be discontinued if there is evidence of tumour growth.
Somatropin must not be used for growth promotion in children with closed epiphyses.
Patients with acute critical illness suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure or similar conditions must not be treated with somatropin (regarding patients undergoing substitution therapy, see section 4.4).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Traceability<br />In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p>The maximum recommended daily dose should not be exceeded (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Introduction of somatropin treatment may result in inhibition of 11&beta;HSD-1 and reduced serum cortisol concentrations. In patients treated with somatropin, previously undiagnosed central (secondary) hypoadrenalism may be unmasked and glucocorticoid replacement may be required. In addition, patients treated with glucocorticoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses, following initiation of somatropin treatment (see section 4.5).</p><p><u>Use with oral oestrogen therapy</u></p><p>If a woman taking somatropin begins oral oestrogen therapy, the dose of somatropin may need to be increased to maintain the serum IGF-1 levels within the normal age-appropriate range. Conversely, if a woman on somatropin discontinues oral oestrogen therapy, the dose of somatropin may need to be reduced to avoid excess of growth hormone and/or side effects (see section 4.5).</p><p><u>Insulin sensitivity</u></p><p>Somatropin may reduce insulin sensitivity. For patients with diabetes mellitus, the insulin dose may require adjustment after somatropin therapy is instituted. Patients with diabetes, glucose intolerance, or additional risk factors for diabetes should be monitored closely during somatropin therapy.</p><p><u>Thyroid function</u></p><p>Growth hormone increases the extrathyroidal conversion of T4 to T3 which may result in a reduction in serum T4 and an increase in serum T3 concentrations. Whereas the peripheral thyroid hormone levels have remained within the reference ranges for healthy subjects, hypothyroidism theoretically may develop in subjects with subclinical hypothyroidism. Consequently monitoring of thyroid function should therefore be conducted in all patients. In patients with hypopituitarism on standard replacement therapy, the potential effect of growth hormone treatment on thyroid function must be closely monitored</p><p>In growth hormone deficiency, secondary to treatment of malignant disease, it is recommended to pay attention to signs of relapse of the malignancy. In childhood cancer survivors, an increased risk of a second neoplasm has been reported in patients treated with somatropin after their first neoplasm. Intracranial tumours, in particular meningiomas, in patients treated with radiation to the head for their first neoplasm, were the most common of these second neoplasms.</p><p>In patients with endocrine disorders, including growth hormone deficiency, slipped epiphyses of the hip may occur more frequently than in the general population. Patients limping during treatment with somatropin should be examined clinically.</p><p><u>Benign intracranial hypertension</u></p><p>In case of severe or recurrent headache, visual problems, nausea and/or vomiting, a fundoscopy for papilloedema is recommended. If papilloedema is confirmed, a diagnosis of benign intracranial hypertension should be considered and, if appropriate, the growth hormone treatment should be discontinued. At present there is insufficient evidence to give specific advice on the continuation of growth hormone treatment in patients with resolved intracranial hypertension. If growth hormone treatment is restarted, careful monitoring for symptoms of intracranial hypertension is necessary.</p><p>Leukaemia</p><p>Leukaemia has been reported in a small number of growth hormone deficiency patients, some of whom have been treated with somatropin. However, there is no evidence that leukaemia incidence is increased in growth hormone recipients without predisposition factors.</p><p><u>Antibodies</u></p><p>A small percentage of patients may develop antibodies to Omnitrope. Omnitrope has given rise to the formation of antibodies in approximately 1% of patients. The binding capacity of these antibodies is low and there is no effect on growth rate. Testing for antibodies to somatropin should be carried out in any patient with otherwise unexplained lack of response.</p><p>Pancreatitis<br />Although rare, pancreatitis should be considered in somatropin-treated patients who develop abdominal pain, especially in children.</p><p>&nbsp;</p><p><em>Elderly patients</em></p><p>Experience in patients above 80&nbsp;years is limited. Elderly patients may be more sensitive to the action of Omnitrope, and therefore may be more prone to develop adverse reactions.</p><p><u>Acute critical illness</u></p><p>The effects of somatropin on recovery were studied in two placebo controlled trials involving 522&nbsp;critically ill adult patients suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma or acute respiratory failure. Mortality was higher in patients treated with 5.3&nbsp;or 8&nbsp;mg somatropin daily compared to patients receiving placebo, 42% vs. 19%. Based on this information, these types of patients should not be treated with somatropin. As there is no information available on the safety of growth hormone substitution therapy in acutely critically ill patients, the benefits of continued treatment in this situation should be weighed against the potential risks involved.</p><p>In all patients developing other or similar acute critical illness, the possible benefit of treatment with somatropin must be weighed against the potential risk involved.</p><p><em>Paediatric population</em></p><p><u>Pancreatitis</u></p><p>Although rare, pancreatitis should be considered in somatropin-treated children who develop abdominal pain.</p><p><u>Prader-Willi syndrome</u></p><p>In patients with PWS, treatment should always be in combination with a calorie-restricted diet.</p><p>There have been reports of fatalities associated with the use of growth hormone in paediatric patients with PWS who had one or more of the following risk factors: severe obesity (those patients exceeding a weight/height of 200%), history of respiratory impairment or sleep apnoea or unidentified respiratory infection. Patients with PWS and one or more of these risk factors may be at greater risk.</p><p>Before initiation of treatment with somatropin patients with PWS should be evaluated for upper airway obstruction, sleep apnoea or respiratory infections should be assessed.</p><p>If during the evaluation of upper airway obstruction, pathological findings are observed, the child should be referred to an Ear, nose and throat (ENT) specialist for treatment and resolution of the respiratory disorder prior to initiating growth hormone treatment.</p><p>Sleep apnoea should be assessed before onset of growth hormone treatment by recognised methods such as polysomnography or overnight oxymetry, and monitored if sleep apnoea is suspected.</p><p>If during treatment with somatropin patients show signs of upper airway obstruction (including onset of or increased snoring), treatment should be interrupted, and a new ENT assessment performed.</p><p>All patients with PWS should be evaluated for sleep apnoea and monitored if sleep apnoea is suspected.Patients should be monitored for signs of respiratory infections, which should be diagnosed as early as possible and treated aggressively.</p><p>All patients with PWS should have effective weight control before and during growth hormone treatment.</p><p>Scoliosis is common in patients with PWS. Scoliosis may progress in any child during rapid growth. Signs of scoliosis should be monitored during treatment.</p><p>Experience with prolonged treatment in adults and in patients with PWS is limited.</p><p><u>Small for gestational age</u></p><p>In short children/adolescents born SGA, other medical reasons or treatments that could explain growth disturbance should be ruled out before starting treatment.</p><p>In SGA children/adolescents it is recommended to measure fasting insulin and blood glucose before start of treatment and annually thereafter. In patients with increased risk for diabetes mellitus (e.g. familial history of diabetes, obesity, severe insulin resistance, acanthosis nigricans) oral glucose tolerance testing (OGTT) should be performed. If overt diabetes occurs, growth hormone should not be administered.</p><p>In SGA children/adolescents it is recommended to measure the IGF-I level before start of treatment and twice a year thereafter. If on repeated measurements IGF-I levels exceed +2&nbsp;SD compared to references for age and pubertal status, the IGF-I&nbsp;/&nbsp;IGFBP-3 ratio could be taken into account to consider dose adjustment.</p><p>Experience in initiating treatment in SGA patients near onset of puberty is limited. It is therefore not recommended to initiate treatment near onset of puberty. Experience in patients with Silver-Russell syndrome is limited.</p><p>Some of the height gain obtained with treating short children/adolescents born SGA with growth hormone may be lost if treatment is stopped before final height is reached.</p><p><u>Chronic renal insufficiency</u></p><p>In chronic renal insufficiency, renal function should be below 50&nbsp;percent of normal before institution of therapy. To verify growth disturbance, growth should be followed for a year preceding institution of therapy. During this period, conservative treatment for renal insufficiency (which includes control of acidosis, hyperparathyroidism and nutritional status) should have been established and should be maintained during treatment.</p><p>The treatment should be discontinued at renal transplantation.</p><p>To date, no data on final height in patients with chronic renal insufficiency treated with Omnitrope are available.</p><p>Omnitrope 5 mg/1.5 ml solution for injection contains benzyl alcohol:</p><p>This medicine contains 9 mg benzyl alcohol in each ml.</p><p>Benzyl alcohol may cause allergic reactions.</p><p>Intravenous administration of benzyl alcohol has been associated with serious adverse events and death in neonates (&ldquo;gasping syndrome&rdquo;). The minimum amount of benzyl alcohol at which toxicity may occur is not known.<br /><br />Advise the parents or legal guardian to not use more than a week in young children (less than 3 years old) without a physician or pharmacist permission.</p><p>Advise pregnant or breast feeding patients that large amounts of benzyl alcohol can be build up in their body and may cause sides effects (called &ldquo;metabolic acidosis&rdquo;).</p><p>Advise patients who have a liver or kidney disease that large amounts of benzyl alcohol can be build up in their body and may cause sides effects (called &ldquo;metabolic acidosis&rdquo;).</p><p>Omnitrope contains sodium This medicine contains less than 1 mmol sodium (23 mg) per ml, i.e. essentially &lsquo;sodium- free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant treatment with glucocorticoids inhibits the growth-promoting effects of Omnitrope. Patients with ACTH deficiency should have their glucocorticoid replacement therapy carefully adjusted to avoid any inhibitory effect on growth.</p><p>Growth hormone decreases the conversion of cortisone to cortisol and may unmask previously undiscovered central hypoadrenalism or render low glucocorticoid replacement doses ineffective (see section 4.4).</p><p>In women on oral oestrogen replacement, a higher dose of growth hormone may be required to achieve the treatment goal (see section 4.4).</p><p>Data from an interaction study performed in growth hormone deficient adults suggests that somatropin administration may increase the clearance of compounds known to be metabolised by cytochrome P450 isoenzymes. The clearance of compounds metabolised by cytochrome P&nbsp;450&nbsp;3A4 (e.g. sex steroids, corticosteroids, anticonvulsants and ciclosporin) may be especially increased resulting in lower plasma levels of these compounds. The clinical significance of this is unknown.</p><p>Also see section&nbsp;4.4 for statements regarding diabetes mellitus and thyroid disorder and section&nbsp;4.2 for statement on oral oestrogen replacement therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no or limited amount of data from the use of somatropin in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section&nbsp;5.3). Somatropin is not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p><u>Breast-feeding</u></p><p>There have been no clinical studies conducted with somatropin containing products in breast-feeding women. It is not known if somatropin is excreted into breast milk, but absorption of intact protein from the gastrointestinal tract of the infant is extremely unlikely. Therefore caution should be exercised when Omnitrope is administered to breast-feeding women.</p><p><u>Fertility</u></p><p>Fertility studies with Omnitrope have not been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Omnitrope has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>a. Summary of the safety profile</u></p><p>Patients with growth hormone deficiency are characterised by extracellular volume deficit. When treatment with somatropin is started this deficit is rapidly corrected. Adverse reactions related to fluid retention, such as peripheral oedema and arthralgia are very common, musculoskeletal stiffness, arthralgia, myalgia and paraesthesia are common. In general these adverse reactions are mild to moderate, arise within the first months of treatment and subside spontaneously or with dose-reduction.</p><p>The incidence of these adverse reactions is related to the administered dose, the age of patients, and possibly inversely related to the age of patients at the onset of growth hormone deficiency.&nbsp;</p><p>Omnitrope has given rise to the formation of antibodies in approximately 1% of the patients. The binding capacity of these antibodies has been low and no clinical changes have been associated with their formation, see section&nbsp;4.4.</p><p><u>b. Tabulated list of adverse reactions</u></p><p>Table&nbsp;1 shows the adverse reactions ranked under headings of System Organ Class and frequency using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data) for each of the indicated conditions.</p><p><span style="text-align:unset">Table 1</span></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Frequency</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms Benign, Malignant and Unspecified (including cysts and polyps)</p></td><td style="vertical-align:top"><p><u>Uncommon:</u> Leukaemia<sup>&dagger;1</sup> <u>Not known:</u> Leukaemia<sup>&dagger;2,3,4,5</sup></p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p><u>Not known:</u> Hypothyroidism**</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and Nutrition Disorders</p></td><td style="vertical-align:top"><p><u>Not known:</u> Type II diabetes mellitus</p></td></tr><tr><td style="vertical-align:top"><p>Nervous System Disorders</p></td><td style="vertical-align:top"><p><u>Common:</u> Paraesthesia*, Benign intracranial hypertension <sup>5</sup>, Carpal Tunnel Syndrome<sup>6</sup> <u>Not known:</u> Benign intracranial hypertension</p><p>1,2,3,4,6</p><p><u>Not known:</u> Headache**</p></td></tr><tr><td style="vertical-align:top"><p>Skin and Subcutaneaous Tissues disorders</p></td><td style="vertical-align:top"><p><u>Common:</u> Rash**, Urticaria** <u>Uncommon:</u> Pruritus**</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal, Connective Tissue and Bone Disorders</p></td><td style="vertical-align:top"><p><u>Very common:</u> Arthralgia*</p><p><u>Common:</u> Myalgia*, Musculoskeletal stiffness*</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p><u>Uncommon:</u> Gynaecomastia**</p></td></tr><tr><td style="vertical-align:top"><p>General Disorders and Administration Site Conditions</p></td><td style="vertical-align:top"><p><u>Very common:</u> Injection site reaction<sup>$</sup>, Oedema peripheral*</p><p><u>Not known:</u> Face oedema*</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p><u>Not known:</u> Blood cortisol decreased<sup>&Dagger;</sup></p></td></tr></tbody></table><p><sup>1</sup> Clinical trials in children with GHD</p><p><sup>2</sup> Clinical trials in children with Turner syndrome</p><p><sup>3</sup> Clinical trials in children with chronic renal insufficiency</p><p><sup>4</sup> Clinical trials in children with SGA</p><p><sup>5</sup> Clinical trials in PWS</p><p><sup>6</sup> Clinical trials in adults with GHD</p><p><br /><span style="text-align:unset">*In general, these adverse effects are mild to moderate, arise within the first months of treatment, and subside spontaneously or with dose-reduction. The incidence of these adverse effects is related to the administered dose, the age of the patients, and possibly inversely related to the age of the patients at the onset of growth hormone deficiency.</span></p><p>$ Transient injection site reactions in children have been reported.</p><p>&Dagger; Clinical significance is unknown</p><p><u>Description of selected adverse reactions</u></p><p>Reduced serum cortisol levels</p><p>Somatropin has been reported to reduce serum cortisol levels, possibly by affecting carrier proteins or by increased hepatic clearance. The clinical relevance of these findings may be limited. Nevertheless, corticosteroid replacement therapy should be optimised before initiation of therapy.</p><p>Prader-Willi syndrome</p><p>In the post-marketing experience rare cases of sudden death have been reported in patients affected by Prader-Willi syndrome treated with somatropin, although no causal relationship has been demonstrated.</p><p>Leukaemia</p><p>Cases of leukaemia (rare or very rare) have been reported in growth hormone deficient children treated with somatropin and included in the post-marketing experience. <u>However, there is no evidence of an increased risk of leukaemia without predisposition factors, such as radiation to the brain or head.</u></p><p>Slipped capital femoral epiphysis and Legg-Calv&eacute;-Perthes disease</p><p>Slipped capital femoral epiphysis and Legg-Calv&eacute;-Perthes disease have been reported in children treated with GH. Slipped capital femoral epiphysis occurs more frequently in case of endocrine disorders and Legg-Calv&eacute;-Perthes is more frequent in case of short stature. But it is unknown if these 2 pathologies are more frequent or not while treated with somatropin. Their diagnosis should be considered in a child with a discomfort or pain in the hip or knee.</p><p>Other adverse drug reactions</p><p>Other adverse drug reactions may be considered somatropin class effects, such as possible hyperglycaemia caused by decreased insulin sensitivity, decreased free thyroxin level and benign intra-cranial hypertension.</p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:405px"><tbody><tr><td style="vertical-align:top; width:402px"><p>- National Pharmacovigilance Center (NPC):</p><p>&middot;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&middot;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp; E-mail:&nbsp; npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: www.ade.sfda.gov.sa</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC states:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</strong></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Symptoms:</em></p><p>Acute overdose could lead initially to hypoglycaemia and subsequently to hyperglycaemia.</p><p>Long-term overdose could result in signs and symptoms consistent with the known effects of human growth hormone excess.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anterior pituitary lobe hormones and analogues, ATC code: H01AC01.</p><p>Omnitrope is a biosimilar medicinal product. Detailed information is available on the website of the European Medicines Agency http://www.ema.europa.eu</p><p><u>Mechanism of action</u></p><p>Somatropin is a potent metabolic hormone of importance for the metabolism of lipids, carbohydrates and proteins. In children with inadequate endogenous growth hormone, somatropin stimulates linear growth and increases growth rate. In adults as well as in children, somatropin maintains a normal body composition by increasing nitrogen retention and stimulation of skeletal muscle growth, and by mobilisation of body fat. Visceral adipose tissue is particularly responsive to somatropin. In addition to enhanced lipolysis, somatropin decreases the uptake of triglycerides into body fat stores. Serum concentrations of IGF-I (Insulin-like Growth Factor-I) and IGFBP3 (Insulin-like Growth Factor Binding Protein 3) are increased by somatropin. In addition, the following actions have been demonstrated.</p><p><u>Pharmacodynamic effects</u></p><p><em><u>Lipid metabolism</u></em></p><p>Somatropin induces hepatic LDL cholesterol receptors, and affects the profile of serum lipids and lipoproteins. In general, administration of somatropin to growth hormone deficient patients results in reduction in serum LDL and apolipoprotein B. A reduction in serum total cholesterol may also be observed.</p><p><em><u>Carbohydrate metabolism</u></em></p><p>Somatropin increases insulin but fasting blood glucose is commonly unchanged. Children with hypopituitarism may experience fasting hypoglycaemia. This condition is reversed by somatropin.</p><p><em><u>Water and mineral metabolism</u></em></p><p>Growth hormone deficiency is associated with decreased plasma and extracellular volumes. Both are rapidly increased after treatment with somatropin. Somatropin induces the retention of sodium, potassium and phosphorus.</p><p><em><u>Bone metabolism</u></em></p><p>Somatropin stimulates the turnover of skeletal bone. Long-term administration of somatropin to growth hormone deficient patients with osteopenia results in an increase in bone mineral content and density at weight-bearing sites.</p><p><em><u>Physical capacity</u></em></p><p>Muscle strength and physical exercise capacity are improved after long-term treatment with somatropin. Somatropin also increases cardiac output, but the mechanism has yet to be clarified. A decrease in peripheral vascular resistance may contribute to this effect.</p><p><em><u>Clinical efficacy and safety</u></em></p><p>In clinical trials in short children/adolescents born SGA doses of 0.033&nbsp;and 0.067&nbsp;mg/kg body weight per day have been used for treatment until final height is reached. In 56 patients who were continuously treated and have reached (near) final height, the mean change from height at start of treatment was +1.90&nbsp;SDS (0.033&nbsp;mg/kg body weight per day) and +2.19&nbsp;SDS (0.067&nbsp;mg/kg body weight per day). Literature data from untreated SGA children/adolescents without early spontaneous catch-up suggest a late growth of 0.5&nbsp;SDS. Long-term safety data are still limited.</p><p>&nbsp;</p><p>Post-marketing study experience:</p><p>An international, non-interventional, non-controlled, longitudinal, open and multicenter, voluntary category 3 PASS designed to record the safety and effectiveness data of 7359 pediatric patients treated with Omnitrope in various indications was conducted by Sandoz between 2006 and 2020 in 11 European countries, in North America, Canada, Australia and Taiwan.<br />The main pediatric indications were: GHD (57.9%), SGA (26.6%), TS (4.9%), ISS (3.3%), PWS (3.2%) and CRI (1.0%). Most patients were na&iuml;ve of previous rhGH treatment (86.0%). Across all indications, the most frequent AEs with a suspected causal relationship to Omnitrope treatment in patients were headache (1.6%), injection site pain (1.1%), injection site hematoma (1.1%) and arthralgia (0.6%), assessed in 7359 pediatric patients (SAF). The majority of AEs assessed as related to Omnitrope treatment were expected based on the SmPC and as known for this type of class of molecule (GH). The intensity of most AEs was mild or moderate.<br />The effectiveness results, assessed in 6589 pediatric patients (EFF consisting of 5671 na&iuml;ve, 915 rhGH pretreated and 3 patients with missing pre-treatment information), show that Omnitrope treatment was effective and resulted in a substantial catch-up growth which are consistent with those reported in observational studies of other approved rhGH medicines: the median H SDS increased effectively from -2.64 at baseline to -1.97 after 1 year and to -0.98 after 5 years of treatment in na&iuml;ve patients, and a median H SDS increased from -1.49 to -1.21 after 1 year and to -0.98 after 5 years of Omnitrope treatment in pre-treated patients. 1628/6589 (24.7%) patients of the EFF reached final height according to physician&rsquo;s opinion (na&iuml;ve: 1289/5671, 22.7%); rhGH pretreated: 338/915, 36.9%). Median (range) final H SDS in na&iuml;ve patients -1.51 (-9.3 to 2.7) and -1.43 (-8.7 to 2.1) in pre-treated patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>The bioavailability of subcutaneously administered somatropin is approximately 80% in both healthy subjects and growth hormone deficient patients.</p><p>A subcutaneous dose of 5&nbsp;mg of Omnitrope 5&nbsp;mg/1.5&nbsp;ml solution for injection in healthy adults results in plasma C<sub>max</sub> and t<sub>max</sub> values of 72&nbsp;&plusmn;&nbsp;28&nbsp;&micro;g/l and 4.0&nbsp;&plusmn;&nbsp;2.0&nbsp;hours, respectively.</p><p>A subcutaneous dose of 5&nbsp;mg of Omnitrope 10&nbsp;mg/1.5&nbsp;ml solution for injection in healthy adults results in plasma C<sub>max</sub> and t<sub>max</sub> values of 74&nbsp;&plusmn;&nbsp;22&nbsp;&micro;g/l and 3.9&nbsp;&plusmn;&nbsp;1.2&nbsp;hours, respectively.</p><p><u>Elimination</u></p><p>The mean terminal half-life of somatropin after intravenous administration in growth hormone deficient adults is about 0.4&nbsp;hours. However, after subcutaneous administration of Omnitrope 5&nbsp;mg/1.5&nbsp;ml, Omnitrope 10&nbsp;mg/1.5&nbsp;ml solution for injection, a half-life of 3&nbsp;hours is achieved. The observed difference is likely due to slow absorption from the injection site following subcutaneous administration.</p><p><u>Special populations</u></p><p>The absolute bioavailability of somatropin seems to be similar in males and females following subcutaneous administration.</p><p>Information about the pharmacokinetics of somatropin in geriatric and paediatric populations, in different races and in patients with renal, hepatic or cardiac insufficiency is either lacking or incomplete.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In studies with Omnitrope regarding subacute toxicity and local tolerance, no clinically relevant effects have been observed.</p><p>In other studies with somatropin regarding general toxicity, local tolerance and reproduction toxicity no clinically relevant effects have been observed.</p><p>With somatropins, <em>in vitro</em> and <em>in vivo</em> genotoxicity studies on gene mutations and induction of chromosome aberrations have been negative.</p><p>An increased chromosome fragility has been observed in one <em>in vitro</em> study on lymphocytes taken from patients after long term treatment with somatropin and following the addition of the radiomimetic drug bleomycin. The clinical significance of this finding is unclear.</p><p>In another study with somatropin, no increase in chromosomal abnormalities was found in the lymphocytes of patients who had received long-term somatropin therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Omnitrope 5&nbsp;mg/1.5&nbsp;ml solution for injection</u></p><p>disodium hydrogen phosphate heptahydrate</p><p>sodium dihydrogen phosphate dihydrate</p><p>mannitol</p><p>poloxamer&nbsp;188</p><p>benzyl alcohol</p><p>water for injections</p><p><u>Omnitrope 10&nbsp;mg/1.5&nbsp;ml solution for injection</u></p><p>disodium hydrogen phosphate heptahydrate</p><p>sodium dihydrogen phosphate dihydrate</p><p>glycine</p><p>poloxamer&nbsp;188</p><p>phenol</p><p>water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Omnitrope 5 mg/1.5 ml solution for injection
2 years.
Omnitrope 10 mg/1.5 ml solution for injection
18 months.
Shelf life after first use
After first use the cartridge should remain in the pen and has to be kept in a refrigerator (2°C   8°C) for a maximum of 28 days. Store and transport refrigerated (2°C   8°C). Do not freeze. Store in the original pen in order to protect from light.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Unopened cartridge</u></p><p>Store and transport refrigerated (2&deg;C&nbsp;‑&nbsp;8&deg;C). Do not freeze. Store in the original package in order to protect from light.</p><p>For storage conditions of the in-use medicinal product, see section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.5&nbsp;ml of solution in a cartridge (colourless type I glass) with plunger on one side (siliconised bromobutyl), a disc (bromobutyl) and a cap (aluminium) on the other side. The glass cartridge is irreversibly integrated in a transparent container and assembled to a plastic mechanism with a threaded rod at one extremity.</p><p>Pack sizes of 1,&nbsp;5&nbsp;and&nbsp;10.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Omnitrope 5&nbsp;mg/1.5&nbsp;ml solution for injection is a sterile, ready-to-use solution for subcutaneous injection filled in a glass cartridge.</p><p>This presentation is intended for multiple use. It should only be administered with SurePal&nbsp;5, an injection device specifically developed for use with Omnitrope 5&nbsp;mg/1.5&nbsp;ml solution for injection. It has to be administered using sterile, disposable pen needles. Patients and caregivers have to receive appropriate training and instruction on the proper use of the Omnitrope cartridges and the pen from the physician or other suitable qualified health professionals.</p><p>Omnitrope 10&nbsp;mg/1.5&nbsp;ml solution for injection is a sterile, ready-to-use solution for subcutaneous injection filled in a glass cartridge.</p><p>This presentation is intended for multiple use. It should only be administered with SurePal&nbsp;10, an injection device specifically developed for use with Omnitrope 10&nbsp;mg/1.5&nbsp;ml solution for injection. It has to be administered using sterile, disposable pen needles. Patients and caregivers have to receive appropriate training and instruction on the proper use of the Omnitrope cartridges and the pen from the physician or other suitable qualified health professionals.</p><p>The following is a general description of the administration process. The manufacturer&rsquo;s instructions with each pen must be followed for loading the cartridge, attaching the injection needle and for the administration.</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hands should be washed.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the solution is cloudy or contains particulate matter, it should not be used. The content must be clear and colourless.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disinfect the rubber membrane of the cartridge with a cleansing swab</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insert the cartridge into SurePal following the instructions for use provided with the pen.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clean the site of injection with an alcohol swab.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer the appropriate dose by subcutaneous injection using a sterile pen needle. Remove the pen needle and dispose of it in accordance with local requirements.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sandoz GmbH
Biochemiestr. 10
A-6250 Kundl
Austria

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>